Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Europe must reinvent warfare for ‘era of shocks,’ NATO’s Vandier says - 2Kendall Jenner addresses long-standing rumor about her sexuality
- 3Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- 4Amazon sued over 'punitive' handling of employee absences
- 5Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- Instructions to Augment the Presentation of Your Kona SUV
- Tata Motors, BMW among automakers set to raise prices in India
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
